Share on StockTwits

BioCryst Pharmaceuticals (NASDAQ:BCRX) has received a consensus rating of “Buy” from the twelve analysts that are covering the stock, Stock Ratings Network reports. Two research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $18.33.

BioCryst Pharmaceuticals (NASDAQ:BCRX) traded up 1.72% on Monday, hitting $14.16. The stock had a trading volume of 192,997 shares. BioCryst Pharmaceuticals has a 52-week low of $4.55 and a 52-week high of $14.62. The stock has a 50-day moving average of $12.44 and a 200-day moving average of $10.70. The company’s market cap is $1.016 billion.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.19) by $0.04. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.32 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. The company’s quarterly revenue was up 79.3% on a year-over-year basis. Analysts expect that BioCryst Pharmaceuticals will post $-0.83 EPS for the current fiscal year.

A number of research firms have recently commented on BCRX. Analysts at JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a research note on Friday, August 8th. They set an “overweight” rating and a $20.00 price target on the stock. Separately, analysts at Wells Fargo & Co. upgraded shares of BioCryst Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, June 23rd. They now have a $17.00 price target on the stock, down previously from $19.00. Finally, analysts at HC Wainwright raised their price target on shares of BioCryst Pharmaceuticals from $21.00 to $24.00 in a research note on Friday, May 30th. They now have a “buy” rating on the stock.

BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) is a biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.